The review, published in The Journal of Clinical Endocrinology & Metabolism, reexamines the widely used concept of “metabolically healthy obesity.” This term has generally been applied to people who meet criteria for obesity but do not currently show a selected group of metabolic abnormalities, such as elevated blood glucose, high blood pressure, abnormal blood lipids or evidence of insulin resistance. The researchers say the label has helped reveal that obesity affects people differently, but it may be too unstable and inconsistent to guide long-term care.

“Metabolically healthy obesity helped researchers recognize that obesity does not affect every person in exactly the same way,” said Eric Ravussin, an LSU Boyd Professor at Pennington Biomedical and co-author of the review. “But the classification is difficult to use as a foundation for long-term treatment because the definitions vary and metabolic health can change. A person who is considered metabolically healthy today may not be metabolically healthy tomorrow.”

The problem begins with the lack of a universal definition. Studies have used different numbers and combinations of metabolic risk factors to classify people as metabolically healthy or unhealthy. Some definitions exclude individuals with diabetes or hypertension, while others permit one or more abnormalities. As a result, two people with similar levels of body fat may receive different classifications depending on the criteria used by a particular study or clinic.

The designation can also change over time. Excess adiposity, particularly when fat accumulates around internal organs, can influence insulin signaling, inflammatory pathways, blood pressure regulation and lipid metabolism. Adipose tissue is biologically active: it releases hormones and signaling molecules that can affect the liver, skeletal muscle, pancreas, cardiovascular system and immune system. A person who has not yet developed measurable metabolic complications may therefore remain at risk of developing them later.

The newer framework discussed by Ravussin and Christian Rodriguez, a postdoctoral researcher at Pennington Biomedical, distinguishes between preclinical obesity and clinical obesity. Preclinical obesity refers to confirmed excess adiposity without current evidence that the condition is impairing organ or tissue function. People in this category may benefit from structured lifestyle programs, ongoing evaluation of cardiometabolic health and individualized discussions about preventive medication, depending on their age, risk factors and health trajectory.

Clinical obesity, by contrast, is defined as excess adiposity accompanied by obesity-related organ or tissue dysfunction or significant limitations in daily activities. Organ dysfunction can include complications affecting glucose regulation, the cardiovascular system, breathing, mobility or other physiological processes. The framework is intended to identify obesity as a disease state when excess fat is not simply present but is producing measurable harm.

This distinction could change how clinicians decide on treatment intensity. Under the older metabolically healthy/unhealthy model, someone without a defined cluster of metabolic abnormalities might receive lifestyle advice and periodic monitoring, even if obesity was affecting mobility, breathing or another aspect of health. The preclinical/clinical approach would encourage physicians to examine the actual consequences of adiposity rather than relying primarily on a narrow list of laboratory thresholds.

It also changes the way treatment success is measured. Weight reduction remains clinically relevant, but the ultimate goal for a person with clinical obesity would be to improve or resolve the dysfunction caused by excess adiposity. For one patient, that might mean better blood glucose control; for another, improved sleep-related breathing, mobility, blood pressure or cardiovascular function. This outcome-based approach could prevent treatment from being judged solely by the number of kilograms lost.

“Moving from the question ‘Is this person metabolically healthy or unhealthy?’ to ‘Is excess adiposity affecting the function of the body?’ gives us a more clinically meaningful way to think about obesity,” Rodriguez said. “The framework allows us to identify people who may benefit from prevention and monitoring while also recognizing when obesity has progressed to a disease state requiring more intensive treatment.”

The proposed model builds on the work of the Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity. Ravussin, Pennington Biomedical researcher Philip Schauer and researcher John Kirwan were among the 56 international experts who contributed to the Commission’s work. The Commission’s framework emphasizes that body size alone does not fully describe the health consequences of obesity and that diagnosis should incorporate evidence of impaired function.

The authors stress that the new approach is still developing. Researchers must validate its diagnostic criteria, determine how organ and tissue dysfunction should be measured consistently and create practical tools that can be used in primary care, specialist clinics and public-health systems. There are also questions about how the framework should account for age, disability, ethnic differences, body-fat distribution and conditions that may have multiple causes.

The review concludes that metabolically healthy obesity remains useful for studying the biological diversity of obesity, but its inconsistent definitions, temporary nature and concentration on a limited set of metabolic markers reduce its value as a long-term clinical category. By focusing on whether excess adiposity is causing functional harm, the preclinical/clinical model could offer physicians a more biologically grounded way to match treatment with individual need.

Subject of Research: Obesity definitions, metabolically healthy obesity, clinical obesity, preclinical obesity and obesity-related organ or tissue dysfunction

Article Title: Does metabolically healthy obesity really exist: going toward new definitions

News Publication Date: 24-Jun-2026

Web References: https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgag247/8715177?redirectedFrom=fulltext; https://doi.org/10.1210/clinem/dgag247; https://www.pbrc.edu

References: Rodriguez C. and Ravussin E., “Does metabolically healthy obesity really exist: going toward new definitions,” The Journal of Clinical Endocrinology & Metabolism, DOI: 10.1210/clinem/dgag247

Image Credits: PBRC; Dr. Christian Rodriguez and LSU Boyd Professor Dr. Eric Ravussin

Keywords: Obesity, metabolically healthy obesity, clinical obesity, preclinical obesity, metabolic health, adiposity, organ dysfunction, diabetes, cardiovascular disease, obesity treatment, pharmacotherapy, bariatric surgery, Pennington Biomedical Research Center

The study’s robust methodology utilized a comprehensive approach to data collection and analysis, emphasizing the importance of accurate metabolic syndrome prediction. By incorporating the new metric of lipid accumulation product (LAP) alongside conventional insulin resistance scores, the researchers sought to establish a more reliable metric for predicting metabolic health risks. Their findings demonstrated that visceral lipid accumulation and LAP critically outperformed insulin resistance scores, providing clinicians with a more effective tool for early intervention.

Metabolic syndrome, as a collection of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels, sets the stage for severe consequences like cardiovascular disease and type 2 diabetes. Early identification of individuals at risk is crucial, and the methods employed in this study showcase significant advances in predictive accuracy. The validation of these findings through AUC (Area Under the Curve) comparisons and decision curve analysis highlights the potential of these new measures to influence clinical practice positively.

The authors’ analysis involved a substantial sample size, ensuring the reliability and validity of their findings. This rigorous approach reinforces the notion that visceral fat is not merely a cosmetic concern but a central player in metabolic dysfunction. With the potential to alter the landscape of metabolic disorder prevention and management, this research invites further exploration into visceral fat’s biological mechanisms and its role in overall health.

What makes this study particularly intriguing is its applicability to specific demographics. The Northern Chinese population exhibits unique dietary and lifestyle factors that may influence their metabolic health. The findings, therefore, have crucial implications not only for this population but also for global health strategies aimed at managing the epidemic of metabolic syndrome. By tailoring prevention strategies to different ethnic and cultural contexts, health organizations could enhance their effectiveness.

Current discussions surrounding metabolic syndrome often lack clarity regarding the best indicators to guide management strategies. The transition from relying solely on insulin resistance scores to incorporating LAP and visceral fat assessments could streamline the diagnostic process, making it more intuitive for healthcare providers. This evolution in practice also calls attention to the need for ongoing education among healthcare professionals to recognize the signs of metabolic syndrome effectively.

Metabolic disorders do not exist in isolation, and the interconnected nature of these conditions necessitates a holistic approach to health. This makes the study’s findings not only relevant but essential for shaping future research directions. As healthcare approaches evolve, integrating comprehensive assessments that include visceral fat distribution could lead to more personalized treatment options, empowering patients to take charge of their metabolic health proactively.

Furthermore, the academic community must seize this opportunity to delve deeper into the various dimensions of body fat distribution and its implications for health outcomes. Future studies could explore further the relationship between visceral fat accumulation and other physiological processes, expanding our understanding of the underlying mechanisms that contribute to metabolic syndrome. Unpacking these intricacies could unveil new therapeutic targets and routines that can mitigate the risks associated with metabolic disorders.

The impact of such research extends beyond individual health, influencing public health policies and strategies aimed at mitigating the burden of metabolic syndrome on healthcare systems worldwide. This underscores the importance of disseminating knowledge to both professionals and the general public. Empowering individuals with information about how visceral fat affects their health could spark behavioral changes that promote better dietary and lifestyle choices.

In a healthcare landscape increasingly dominated by technology, the integration of predictive analytics could greatly enhance the application of the study’s findings. Utilizing AI and machine learning models to analyze large datasets and identify patterns associated with visceral fat and metabolic syndrome could lead to predictive tools that healthcare providers can employ during patient evaluations. This integration of technology can ultimately transform patient outcomes through earlier and more accurate diagnoses.

In conclusion, Liu et al.’s research signifies a crucial shift in understanding metabolic syndrome. By emphasizing the role of visceral fat and the efficacy of lipid accumulation products as predictive measures, this study lays the groundwork for enhanced screening and management strategies. As the weight of this evidence grows, healthcare professionals and policymakers alike must adapt their approaches to prioritize visceral fat assessment as a cornerstone of metabolic health evaluation, ultimately leading to more effective interventions and improved patient care.

As we continue to navigate the complexities of metabolic health, this research serves as a clarion call for innovation and adaptability in our approaches. The insights derived from Liu and colleagues’ study not only unveil the critical importance of visceral fat in assessing metabolic syndrome but also remind us of the ongoing need for research that pushes boundaries. The findings may influence clinical practices and further inspire future research endeavors aimed at confronting the global challenges posed by metabolic disorders.

Through collaboration across disciplines – endocrinology, nutrition, public health, and technology – we can endeavor to reshape the narrative surrounding metabolic syndrome. It is imperative that we collectively acknowledge the implications of visceral fat and work towards integrative strategies that protect and promote the metabolic health of all populations, thereby paving the way towards a healthier future.

Subject of Research: Visceral lipid accumulation and its role in metabolic syndrome prediction.

Article Title: Visceral lipid accumulation and lipid accumulation product outperform insulin resistance score for metabolic syndrome prediction in Northern Chinese adults: validation through AUC comparison and decision curve analysis.

Article References:

Liu, Q., Guan, X., Wang, LJ. et al. Visceral lipid accumulation and lipid accumulation product outperform insulin resistance score for metabolic syndrome prediction in Northern Chinese adults: validation through AUC comparison and decision curve analysis.
BMC Endocr Disord 25, 265 (2025). https://doi.org/10.1186/s12902-025-02086-w

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02086-w

Keywords: Metabolic syndrome, visceral fat, lipid accumulation product, insulin resistance, predictive analytics.

Traditional markers like BMI, though widely used due to their simplicity, have increasingly been criticized for their inability to accurately reflect body fat distribution and quantity, factors which are closely linked to metabolic health risks. This is where RFM introduces a refined lens, incorporating height and waist measurements into a ratio that more directly estimates fat mass relative to total body size. The TLGS researchers capitalized on this method to provide robust evidence supporting RFM’s predictive validity, answering a critical question in epidemiology and clinical practice: how can we better quantify obesity-linked risk to forecast diabetes development?

The Tehran Lipid and Glucose Study cohort, a diverse and representative population sample, offered an ideal foundation for this inquiry. Over the decade-long follow-up, participants’ anthropometric data, lifestyle habits, and metabolic biomarkers were periodically recorded. Utilizing advanced statistical modeling, Masrouri and colleagues identified that individuals with elevated RFM values demonstrated a markedly higher hazard ratio for incident T2DM, independent of confounding variables such as age, sex, and other cardiovascular risk factors. This relationship persisted even when adjusting for BMI and WC, underscoring RFM’s unique and potent association with diabetes risk.

Biologically, this association is compelling. Adipose tissue plays a critical role not only as an energy reservoir but also as an active endocrine organ influencing insulin sensitivity and inflammatory responses. The excess fat mass captured by RFM likely encompasses visceral adiposity—a metabolically active fat depot implicated in insulin resistance and beta-cell dysfunction. Since BMI cannot distinguish between lean and fat mass and WC may be influenced by factors such as abdominal distension unrelated to fat, RFM’s design offers a more nuanced reflection of the adipose tissue burden relevant to pathophysiologic mechanisms driving T2DM.

Further dissecting the findings, the study illuminated nuances in sex-specific responses. Women, whose fat distribution often differs markedly from men, showed slightly different risk gradients, pointing to the need for sex-tailored cutoffs when interpreting RFM in clinical settings. Such insights could fuel personalized medicine approaches, enabling healthcare providers to stratify risk with greater precision and implement lifestyle or pharmacological interventions earlier, potentially forestalling the progression to overt diabetes.

The implications extend beyond individual risk prediction to public health strategy. With type 2 diabetes incidence escalating globally, particularly in urbanizing regions undergoing nutritional and lifestyle transitions, accessible and reliable tools for risk stratification are urgently needed. RFM provides a simple, non-invasive, and inexpensive metric easily derived from routine clinical or community health screenings. Incorporating RFM into screening protocols could enhance the identification of high-risk individuals otherwise mislabeled by traditional metrics.

Moreover, this study invites a revisitation of existing guidelines that prioritize BMI and WC as primary markers of metabolic risk. Given the mounting evidence supporting RFM, medical societies and policy frameworks might consider revising diagnostic criteria or recommending routine calculation of RFM during health assessments. Encouraging such paradigm shifts requires continued dissemination of these findings through clinical channels and engagement with policymakers, emphasizing the tangible benefit in reducing diabetes-related morbidity and healthcare burden.

From a methodological perspective, the TLGS team’s approach exemplifies rigorous longitudinal epidemiology, leveraging a well-characterized cohort, repeated measurements, and sophisticated analytical techniques to tease out complex associations. Their work bolsters growing consensus that refined anthropometric indices hold key insights into chronic disease etiology, warranting broader application both in research and clinical arenas. This may stimulate further validation studies across diverse populations or integration with emerging technologies like imaging or metabolomics for comprehensive risk profiling.

An intriguing aspect arising from the study’s data is the dynamic nature of RFM over time and its relationship with diabetes risk trajectories. Rather than viewing fat mass as static, longitudinal tracking allowed researchers to capture evolving patterns, potentially identifying critical windows where interventions might exert greatest benefit. Importantly, since RFM calculation requires only basic anthropometric inputs, it can be feasibly repeated in various settings, amplifying its utility for monitoring disease risk progression or response to therapy.

Critically, the study recognized limitations inherent in observational data, including residual confounding and generalizability outside the Iranian demographic context. Nevertheless, by accounting for a wide range of lifestyle and metabolic factors, the investigators minimized bias, and their findings nevertheless echo parallel reports from other cohorts, reinforcing RFM’s robustness as a predictive metric. Future research might focus on mechanistic explorations linking RFM changes to molecular pathways underpinning glucose dysregulation.

This research underscores an indispensable shift toward precision in obesity-related risk stratification, transcending the one-size-fits-all paradigm traditionally dominated by BMI. For clinicians grappling with diabetes prevention in an era of escalating prevalence and complex patient phenotypes, adopting RFM-centric frameworks could enhance screening accuracy. Early identification of individuals most susceptible to metabolic dysfunction opens avenues for tailored interventions ranging from dietary counseling to pharmacotherapy, potentially altering disease courses at a population scale.

Beyond clinical and epidemiological dimensions, the study raises awareness about the nuanced roles of adiposity beyond simple weight indices. RFM encapsulates the intricate interplay between body fat distribution and metabolic health, spotlighting the perils of underestimating fat’s biological activity when relying on crude metrics. Embracing this complexity can inspire innovative public health messaging and empower individuals with clearer understanding of their personal health markers.

In synthesizing these insights, the researchers advocate for a paradigm shift in diabetes risk assessment tools to encompass relative fat mass, which captures metabolic nuances overlooked by BMI and WC. This alignment with metabolic realities promises improved preventive strategies essential in curbing the global diabetes epidemic. As clinicians, researchers, and policymakers absorb these findings, RFM may soon become a cornerstone in metabolic health evaluation.

Ultimately, this study not only clarifies a critical link between fat mass and diabetes risk but also enriches the toolbox for addressing one of the most pressing public health challenges of our time. By refining risk estimation through RFM, science advances towards more effective, individualized approaches that hold promise for a healthier future free from the burdens of type 2 diabetes.

Subject of Research: Association between relative fat mass and incidence of type 2 diabetes mellitus

Article Title: Association of relative fat mass with the incidence of type 2 diabetes: over a decade follow-up from the TLGS

Article References:
Masrouri, S., Ebrahimi, N., Soraneh, S. et al. Association of relative fat mass with the incidence of type 2 diabetes: over a decade follow-up from the TLGS. Int J Obes (2025). https://doi.org/10.1038/s41366-025-01858-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41366-025-01858-7